EUVIMEDSkopri EUVIMED
Validierungsstudie

Development of the health economic model for type 2 diabetes considering glycaemic variability

Zhuoqi Gu iD, Lei Chen iD, Kexin Zhan, Xiaoyu Xi iD, Jing Wang iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70451 ↗

At a glance

Validierungsstudie in Diabetes, Obesity and Metabolism, 2026. Written by Zhuoqi Gu and 4 co-authors. Institution: The Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University, Nanjing, China. Major MEDLINE topics: Diabetes Mellitus, Type 2, Blood Glucose, Models, Economic. 52 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objective

This study aimed to develop and validate a health‐economic model incorporating glycaemic variability to support the economic evaluation of novel interventions.

Methods

We developed a Monte Carlo‐based Markov model, primarily using data from the United Kingdom Prospective Diabetes Study. An innovative glycaemic variability module was constructed, with its key parameter being the time in range (TIR). TIR was defined as the percentage of time a patient's glucose level remained within the target range of 3.9–10.0 mmol/L. The module was parameterized based on quantitative clinical evidence. The base model underwent face, internal, and external validation, with performance assessed using the R 2 , root mean square percentage error (RMSPE) and symmetric mean absolute percentage error (SMAPE). To evaluate the structural uncertainty introduced by the new module, we conducted an exploratory scenario analysis in which the incremental improvement in TIR was modelled from 0% to 100%.

Results

The model showed good overall reliability. Specifically, face validity was confirmed, while internal and external validation both demonstrated R 2 values exceeding 0.95. For the internal and external validation, the RMSPE was 0.328 and 0.347, and the corresponding SMAPE values were 0.175 and 0.279, respectively. The exploratory scenario analysis supported the structural validity of the module. Over the first decade, the cumulative incidence of background retinopathy, microalbuminuria, peripheral vascular disease, and mortality decreased as TIR improved. However, the incidence gaps narrowed in the long run, which was consistent with clinical observations.

Conclusion

This study developed and validated a health‐economic model incorporating glycaemic variability, which provides a potentially robust tool to inform economic evaluations of novel interventions.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Blood GlucoseModels, EconomicHumansMarkov ChainsMonte Carlo MethodUnited KingdomCost-Benefit AnalysisReproducibility of ResultsGlycemic ControlHypoglycemic AgentsGlycated HemoglobinProspective Studies

Author keywords

diabetes type 2glycaemic variabilityhealth economic modeltime in range

Substances

Blood GlucoseHypoglycemic AgentsGlycated Hemoglobin

Authors and institutions

  • The Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University, Nanjing, China.

ORCID profiles: Zhuoqi Gu, Lei Chen, Xiaoyu Xi, Jing Wang

Cite

APA

Gu, Z., Chen, L., Zhan, K., Xi, X., & Wang, J. (2026). Development of the health economic model for type 2 diabetes considering glycaemic variability. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70451

Vancouver

Gu Z, Chen L, Zhan K, Xi X, Wang J. Development of the health economic model for type 2 diabetes considering glycaemic variability. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70451

BibTeX
@article{Gu2026,
  author = {Gu, Zhuoqi and Chen, Lei and Zhan, Kexin and Xi, Xiaoyu and Wang, Jing},
  title = {Development of the health economic model for type 2 diabetes considering glycaemic variability},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70451}
}
Start for free →